See also this year's filing and all EDGAR filings for this company.
PDF Report 0001772028_2022_Scopus_Biopharma_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | Missing logo | subcommand.report | {} |
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.7710821035508951, 'aggregate_val': 20748009, 'exp_sum': 11714877, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 9033132, 'ResearchAndDevelopmentExpense': 2681745, 'remainder_Expenses': 0}} |
| warning | Excluding company: variable exceeds outlier threshold | pre-agg | {'variable': 'ComprehensiveNetIncome', 'value': -11528128, 'size_variable': 'Assets', 'size_value': 392265, 'ratio': 29.4, 'threshold': 20} |
Graph
Absolute values for 0001772028, Scopus Biopharma Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 8,184,875 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 2,840 |
| 3 | remainder_Assets | 0 |
| 4 | LiabilitiesCurrent | 4,170,266 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 12,611,169 |
| 9 | ResearchAndDevelopmentExpense | 15,023,450 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 681,210 |
| 13 | remainder_ComprehensiveNetIncome | -18,586 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 8,187,715 |
| 1 | Liabilities | 4,170,266 |
| 2 | Expenses | 27,634,619 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 4,017,449 |
| 5 | NetIncome | -26,953,409 |
| 6 | ComprehensiveNetIncome | -26,962,702 |
| 7 | BaseVar | 20,346,198 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -2.95 |
| 9 | EconomicCapitalRatio | 0.704 |
Edgar->Model Mapping
Feature Distribution
Change over Time
